康柏西普玻璃体腔注射联合复合式小梁切除及全视网膜光凝治疗新生血管性青光眼

Conbercept Trabeculectomy and Pan-retinal Photocoagulation for Neovascular Glaucoma

目的观察康柏西普玻璃体腔注射联合复合式小梁切除术及全视网膜光凝治疗新生血管性青光眼的临床价值。方法随机将该院2018年4月—2019年4月收治的90例新生血管性青光眼患者分为两组,每组45例。对照组行复合式小梁切除术,观察组在上述基础上行康柏西普玻璃体腔注射+全视网膜光凝。比较两组总有效率、眼压以及视力等指标。结果①观察组总有效率91.11%(41/45)明显优于对照组71.11%(32/45),差异有统计学意义(χ^2=13.763,P<0.05);②观察组并发症发生率(4.44%)低于对照组(6.67%),差异无统计学意义(χ^2=0.852,P>0.05)。结论康柏西普玻璃体腔注射联合复合式小梁切除术及全视网膜光凝可有效治疗新生血管性青光眼。

Objective To observe the clinical value of intravitreal injection of Conbercept combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma. Methods Randomly divide90 neovascular glaucoma patients admitted to the hospital from April 2018 to April 2019 into two groups, each with 45 cases. The control group underwent compound trabeculectomy, and the observation group underwent intravitreal injection of conbercept + panretinal photocoagulation on the above basis. The total effective rate, intraocular pressure and visual acuity were compared between the two groups. Results 1.The total effective rate of the observation group91.11%(41/45) was significantly better than that of the control group 71.11%(32/45), the difference was statistically significant(χ^2=13.763, P<0.05);2. The observation group was concurrent incidence of symptom(4.44%) was lower than that of the control group(6.67%), the difference was not statistically significant(χ^2=0.852, P >0.05).Conclusion Conbercept intravitreal injection combined with compound trabeculectomy and panretinal photocoagulation can effectively treat neovascular glaucoma.